KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Preferred Stock Liabilities: 2016-2017

  • Moderna's Preferred Stock Liabilities changed negligibly% to $1.2 billion in Q4 2017 from the same period last year, while for Dec 2017 it was $1.2 billion, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.2 billion for FY2017, which is negligibly% changed negligibly from last year.
  • Moderna's Preferred Stock Liabilities amounted to $1.2 billion in Q4 2017, which was down 0.00% from $1.2 billion recorded in Q4 2016.
  • Over the past 5 years, Moderna's Preferred Stock Liabilities peaked at $1.2 billion during Q4 2016, and registered a low of $1.2 billion during Q4 2016.
  • Moreover, its 2-year median value for Preferred Stock Liabilities was $1.2 billion (2017), whereas its average is $1.2 billion.